Neuralstem: First Patient Treated In Phase II Of ALS Stem Cell Trial – RTT News
|
Neuralstem: First Patient Treated In Phase II Of ALS Stem Cell Trial
RTT News Neuralstem Inc. (CUR: Quote) announced that the first patient was treated in its Phase II trial using NSI-566 spinal cord-derived neural stem cells in the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig’s disease) at Emory University … |
